Side by side
Semaglutide vs Survodutide
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Semaglutide | Survodutide | |
|---|---|---|
| What it is | A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly. | A GLP-1 and glucagon dual agonist in phase 3, and one of the more advanced candidates for fatty liver disease rather than weight alone. |
| EvidenceHow much human evidence exists, not how well it works. | Approved | Clinical trials |
| Regulatory statusReviewed 2026-08-12 | Approved by the FDA as a prescription medicine for type 2 diabetes and for chronic weight management. Material sold as a research chemical is not the approved product — is not manufactured to the same standard — and is not legal to sell for human use. | Not approved in any jurisdiction. In phase 3 development for obesity and for metabolic dysfunction-associated steatohepatitis. Anything sold as survodutide today is a research chemical. |
| Routes | Subcutaneous | Subcutaneous |
| Half-life | 168 hours | 150 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.50/mg | $4.87/mg |
| Median per mg | $6.70/mg | $10.00/mg |
| Vendors with a price | 28 | 12 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze. Discard if the solution is cloudy or has visible particles. | Refrigerated at 2–8 °C. Do not freeze once mixed. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.